FDA Panel Finds Fatal Risks In GE, Covidien MRI Drugs
The majority of members on a U.S. Food and Drug Administration advisory committee has reportedly found that GE Healthcare's Omniscan and Covidien's Optimark — both magnetic resonance imaging drugs — appear...To view the full article, register now.
Already a subscriber? Click here to view full article